A personalized peptide vaccine designed to target a prostate cancer patient's specific tumor mutations generated strong immune responses, especially when both HLA class I and II peptides were included.
PSA undetectable for 51 monthsPatient with metastatic prostate cancer showed sustained disease control after personalized peptide vaccination targeting tumor-specific mutations
What the researchers found
A patient with metastatic castration-sensitive prostate cancer received two sequential personalized peptide vaccines over 33 months. The first vaccine, containing only HLA class I binding peptides, induced just one CD4+ T-cell response after 21 vaccinations. The second vaccine, incorporating both HLA class I and class II binding peptides, triggered multiple strong and durable CD4+ and CD8+ T-cell responses after only 6 vaccinations. The immune responses were polyfunctional (producing IFNγ, TNF-α, IL-2, and CD154). The patient's PSA remained undetectable for 51 months.
Why it matters
Metastatic prostate cancer has limited treatment options and a poor 5-year survival rate. This case demonstrates that personalized peptide vaccines targeting tumor-specific mutations can generate robust anti-tumor immune responses, and that including both HLA class I and II peptides dramatically improves vaccine efficacy — a critical design insight for future cancer vaccine trials.
The numbers in context
33 months of vaccination · 1st vaccine: 1 response after 21 doses · 2nd vaccine: multiple responses after 6 doses · PSA undetectable for 51 months · 4 T-cell markers measured
How the study worked
Case report of a single patient with metastatic castration-sensitive prostate cancer in remission. Somatic tumor mutations were identified via genomic analysis. The patient received two sequential peptide vaccines: first with HLA class I peptides only, then with both HLA class I and II peptides. Vaccine-induced T-cell responses were measured using intracellular cytokine staining after 12-day in vitro expansion, assessing four activation markers (IFNγ, TNF-α, IL-2, CD154).
Who was studied
Single male patient with metastatic castration-sensitive prostate cancer in remission
What this study cannot tell us
This is a single-patient case report, so the results cannot be generalized. It is impossible to determine whether the sustained PSA suppression was due to the vaccine, other treatments, or the natural disease course. The in vitro expansion period before immune monitoring may amplify responses beyond what occurs naturally in the patient.
How to read the evidence
This is a single-patient case report — the lowest level of clinical evidence. While the immune response data is compelling and well-documented, a single case cannot prove causation or predict outcomes for other patients.
When this study was published
Published in 2023, this study reflects the rapidly advancing field of personalized cancer vaccines. The design insight about including both HLA class I and II peptides is directly informing ongoing vaccine trial designs.
The bigger picture
Cancer vaccines are moving toward personalization — designing peptides that match each patient's unique tumor mutations. This case supports the approach and adds an important practical finding: including peptides that activate both helper and killer T cells is far more effective than targeting killers alone. This insight could shape the design of upcoming neoantigen vaccine trials across cancer types.
Questions still open
- Would this dual HLA class I and II peptide approach produce similar results in a larger cohort of prostate cancer patients?
- Can personalized neoantigen peptide vaccines be combined with immune checkpoint inhibitors for enhanced anti-tumor effects?
- How long do the vaccine-induced T-cell responses persist after vaccination stops?
Common questions
What is a neoantigen peptide vaccine?
Why did the second vaccine work so much better than the first?
Read the original research
Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.
Frontiers in immunology, 14, 1271449
Citation
Zelba, Henning; Rabsteyn, Armin; Bartsch, Oliver; Kyzirakos, Christina; Kayser, Simone; Seibold, Marcel; Harter, Johannes; Latzer, Pauline; Hadaschik, Dirk; Battke, Florian; Golf, Alexander; Rettig, Matthew B; Biskup, Saskia. (2023). Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer.. Frontiers in immunology, 14, 1271449. https://doi.org/10.3389/fimmu.2023.1271449